Skip to main content
Search
Main content

Publications

Our scientific output and findings

From groundbreaking discoveries in basic science to innovative clinical insights, our publications showcase the breadth and depth of research taking place at the UK DRI. 

N Engl J Med
Published

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Authors
Stephen Salloway, Reisa Sperling, Nick C Fox, Kaj Blennow, William Klunk, Murray Raskind, Marwan Sabbagh, Lawrence S Honig, Anton P Porsteinsson, Steven Ferris, Marcel Reichert, Nzeera Ketter, Bijan Nejadnik, Volkmar Guenzler, Maja Miloslavsky, Daniel Wang, Yuan Lu, Julia Lull, Iulia Cristina Tudor, Enchi Liu, Michael Grundman, Eric Yuen, Ronald Black, H Robert Brashear,
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
N Engl J Med
Published

TREM2 variants in Alzheimer's disease.

Authors
Rita Guerreiro, Aleksandra Wojtas, Jose Bras, Minerva Carrasquillo, Ekaterina Rogaeva, Elisa Majounie, Carlos Cruchaga, Celeste Sassi, John S K Kauwe, Steven Younkin, Lilinaz Hazrati, John Collinge, Jennifer Pocock, Tammaryn Lashley, Julie Williams, Jean-Charles Lambert, Philippe Amouyel, Alison Goate, Rosa Rademakers, Kevin Morgan, John Powell, Peter St George-Hyslop, Andrew Singleton, John Hardy,
TREM2 variants in Alzheimer's disease.
PLoS One
Published

Trans-synaptic spread of tau pathology in vivo.

Authors
Li Liu, Valerie Drouet, Jessica W Wu, Menno P Witter, Scott A Small, Catherine Clelland, Karen Duff
Trans-synaptic spread of tau pathology in vivo.
Cell
Published

Direct observation of the interconversion of normal and toxic forms of α-synuclein.

Authors
Nunilo Cremades, Samuel I A Cohen, Emma Deas, Andrey Y Abramov, Allen Y Chen, Angel Orte, Massimo Sandal, Richard W Clarke, Paul Dunne, Francesco A Aprile, Carlos W Bertoncini, Nicholas W Wood, Tuomas P J Knowles, Christopher M Dobson, David Klenerman
Direct observation of the interconversion of normal and toxic forms of α-synuclein.